• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The results of molecular genetic testing for RET proto-oncogene mutations in patients with medullary thyroid carcinoma in a referral center after the two decade period.在一个转诊中心,经过二十年时间后,对甲状腺髓样癌患者进行RET原癌基因突变分子遗传学检测的结果。
Hippokratia. 2016 Jul-Sep;20(3):187-191.
2
RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.甲状腺髓样癌患者及其亲属的RET基因筛查:一个中心807例个体的经验
J Clin Endocrinol Metab. 2007 Dec;92(12):4725-9. doi: 10.1210/jc.2007-1005. Epub 2007 Sep 25.
3
Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.散发性甲状腺髓样癌患者RET原癌基因种系突变频率较低。
Clin Endocrinol (Oxf). 1995 Jul;43(1):123-7. doi: 10.1111/j.1365-2265.1995.tb01903.x.
4
Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinoma.散发性甲状腺髓样癌中RET原癌基因的体细胞突变。
Clin Endocrinol (Oxf). 1996 Mar;44(3):249-57. doi: 10.1046/j.1365-2265.1996.681503.x.
5
RAS proto-oncogene in medullary thyroid carcinoma.甲状腺髓样癌中的RAS原癌基因。
Endocr Relat Cancer. 2015 Oct;22(5):R235-52. doi: 10.1530/ERC-15-0070.
6
Proto-Oncogene Mutational Analysis in 45 Iranian Patients Affected with Medullary Thyroid Carcinoma: Report of a New Variant.45例伊朗甲状腺髓样癌患者的原癌基因突变分析:一种新变异的报告
J Thyroid Res. 2021 Nov 3;2021:7250870. doi: 10.1155/2021/7250870. eCollection 2021.
7
RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A.在患有2A型多发性内分泌腺瘤的韩国家庭中,RET原癌基因突变仅限于密码子634和618。
Thyroid. 2004 Oct;14(10):813-8. doi: 10.1089/thy.2004.14.813.
8
Polymorphisms in the RET proto-oncogene and the phenotypic presentation of familial medullary thyroid carcinoma.RET原癌基因多态性与家族性甲状腺髓样癌的表型表现
Thyroid. 2004 Oct;14(10):848-52. doi: 10.1089/thy.2004.14.848.
9
Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.1995年鲁道夫·魏尔啸奖。RET原癌基因突变分析在2型多发性内分泌腺瘤病(MEN 2)基因携带者诊断以及散发性和家族性甲状腺髓样癌与嗜铬细胞瘤鉴别中的作用
Verh Dtsch Ges Pathol. 1995;79:L-LV.
10
Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence.散发性甲状腺髓样癌中ret原癌基因的体细胞突变并不局限于第16外显子,且与肿瘤复发相关。
J Clin Endocrinol Metab. 1996 Apr;81(4):1619-22. doi: 10.1210/jcem.81.4.8636377.

引用本文的文献

1
Characteristics of RET gene mutations in Vietnamese medullary thyroid carcinoma patients: a single-center analysis.越南甲状腺髓样癌患者RET基因突变特征:单中心分析
J Pathol Transl Med. 2025 Mar;59(2):125-132. doi: 10.4132/jptm.2025.01.18. Epub 2025 Mar 14.

本文引用的文献

1
[Medullary thyroid carcinoma].甲状腺髓样癌
Internist (Berl). 2015 Sep;56(9):1019-31. doi: 10.1007/s00108-014-3638-z.
2
Haplotype Frequency of G691S/S904S in the RET Proto-Onco-gene in Patients with Medullary Thyroid Carcinoma.甲状腺髓样癌患者RET原癌基因中G691S/S904S单倍型频率
Iran J Public Health. 2014 Feb;43(2):235-40.
3
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.美国甲状腺协会修订的甲状腺髓样癌管理指南。
Thyroid. 2015 Jun;25(6):567-610. doi: 10.1089/thy.2014.0335.
4
Genetic screening of patients with medullary thyroid cancer in a referral center in Greece during the past two decades.在过去的二十年中,对希腊一家转诊中心的甲状腺髓样癌患者进行了基因筛查。
Eur J Endocrinol. 2015 Apr;172(4):501-9. doi: 10.1530/EJE-14-0817. Epub 2015 Jan 26.
5
Imaging, genetic testing, and biomarker assessment of follicular cell-derived thyroid cancer.滤泡细胞源性甲状腺癌的影像学、基因检测及生物标志物评估
Ann Med. 2014 Sep;46(6):409-16. doi: 10.3109/07853890.2014.923739. Epub 2014 Jul 2.
6
2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer.2012 年欧洲甲状腺协会关于甲状腺髓样癌基因检测及其临床后果的指南。
Eur Thyroid J. 2013 Jan;1(4):216-31. doi: 10.1159/000346174. Epub 2012 Dec 19.
7
Update on the cytologic and molecular features of medullary thyroid carcinoma.甲状腺髓样癌的细胞学和分子特征的最新进展。
Adv Anat Pathol. 2014 Jan;21(1):26-35. doi: 10.1097/PAP.0000000000000004.
8
Molecular epidemiology of multiple endocrine neoplasia 2: implications for RET screening in the new millenium.多发性内分泌腺瘤 2 型的分子流行病学:对新千年 RET 筛查的意义。
Eur J Endocrinol. 2013 Feb 15;168(3):307-14. doi: 10.1530/EJE-12-0919. Print 2013 Mar.
9
Risk factors for sporadic medullary thyroid carcinoma.散发性甲状腺髓样癌的危险因素。
Eur J Cancer Prev. 2013 May;22(3):262-7. doi: 10.1097/CEJ.0b013e3283592c78.
10
Make way for the 'next generation': application and prospects for genome-wide, epigenome-specific technologies in endocrine research.为“下一代”让路:全基因组、表观基因组特异性技术在内分泌研究中的应用及前景。
J Mol Endocrinol. 2012 May 29;49(1):R19-27. doi: 10.1530/JME-12-0045. Print 2012 Aug.

在一个转诊中心,经过二十年时间后,对甲状腺髓样癌患者进行RET原癌基因突变分子遗传学检测的结果。

The results of molecular genetic testing for RET proto-oncogene mutations in patients with medullary thyroid carcinoma in a referral center after the two decade period.

作者信息

Rovcanin B, Damjanovic S, Zivaljevic V, Diklic A, Jovanovic M, Paunovic I

机构信息

Center for Endocrine Surgery, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

Institute of Endocrinology, Diabetes and Metabolic Disease, Clinical Center of Serbia, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

出版信息

Hippokratia. 2016 Jul-Sep;20(3):187-191.

PMID:29097883
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5654434/
Abstract

BACKGROUND

Medullary thyroid carcinoma (MTC) is a type of thyroid neoplasm which originates from parafollicular cells, and it is commonly diagnosed by calcitonin screening. Besides the sporadic form, the heritable form of MTC is characterized by constitutive activation of the RET (REarranged during Transfection) proto-oncogene caused by different mutations.

METHOD

We collected data regarding RET genetic screening performed in the Center for Endocrine Surgery in Belgrade during a 20-year-period. The study group included 249 MTC patients who were genetically tested for RET mutations by Sanger's sequencing method.

RESULTS

Genetic screening of the study population revealed nine different mutations of the RET gene in 42 carriers. The most common mutation was C634F, and it has been detected in 31 % (13/42) of individuals, while C618R, L790F, and S904S were present in only 2 % (1/42) each in the study group. Detected mutations were unequally distributed in different RET gene exons. Among MTC patients, 67 % (28/42) had mutation harbored in exon 11, while the rarest mutation was located in exons 10 and 15, each present in only 2 % (1/42) of patients.

CONCLUSIONS

The RET gene mutation profile has a unique distribution in this study population when compared with the other European populations. The mutations in codon 634 are most common; therefore the cost-reducing genetic screening should primarily target this codon, and if the negative outcome appears, then other codons should be examined in the order that depends on their occurrence. Hippokratia 2016, 20(3): 187-191.

摘要

背景

甲状腺髓样癌(MTC)是一种起源于滤泡旁细胞的甲状腺肿瘤,通常通过降钙素筛查进行诊断。除散发型外,遗传性MTC的特征是由不同突变导致的RET(转染期间重排)原癌基因的组成性激活。

方法

我们收集了贝尔格莱德内分泌外科中心在20年期间进行的RET基因筛查数据。研究组包括249例通过桑格测序法进行RET基因突变基因检测的MTC患者。

结果

对研究人群的基因筛查发现42名携带者中有9种不同的RET基因突变。最常见的突变是C634F,在31%(13/42)的个体中被检测到,而C618R、L790F和S904S在研究组中各仅占2%(1/42)。检测到的突变在不同的RET基因外显子中分布不均。在MTC患者中,67%(28/42)的突变位于外显子11,而最罕见的突变位于外显子10和15,各仅在2%(1/42)的患者中出现。

结论

与其他欧洲人群相比,本研究人群的RET基因突变谱具有独特的分布。密码子634处的突变最为常见;因此,降低成本的基因筛查应主要针对该密码子,如果结果为阴性,则应按照其出现频率的顺序检查其他密码子。《希波克拉底》2016年,20(3): 187 - 191。